Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 USD | -2.56% | +3.64% | -35.96% |
May. 10 | Transcript : Protalix BioTherapeutics, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
May. 10 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Its low valuation, with P/E ratio at 9.5 and 1.81 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-35.96% | 83.58M | - | ||
+33.63% | 50.93B | B- | ||
-0.09% | 42.12B | B | ||
+49.62% | 42.05B | A | ||
-4.96% | 29.18B | C | ||
+11.18% | 26.02B | B- | ||
-21.95% | 18.9B | B | ||
+8.61% | 13.21B | B+ | ||
+24.73% | 12.17B | B+ | ||
+28.31% | 12.16B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PLX Stock
- Ratings Protalix BioTherapeutics, Inc.